To overcome the limitation of the short circulating half-life of small biotherapeutics, a large variety of half-life extension strategies have emerged in the last decades. The albumin-binding domain antibody (AlbudAb) was widely used to extend the half-lives of short-lived drugs.
For more: https://half-life-extension.cr....eative-biolabs.com/a
Like
Comment
Share
